TKI-话题@MedSci

#TKI#

128篇内容 | 3906人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384163, encodeId=b805138416364, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Lancet Haematol：MMR稳定慢性粒细胞白血病患者TKI降阶梯治疗是否可行？, objectType=article, longId=105907, objectId=926910590ebd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=926910590ebd, replyNumber=0, likeNumber=78, createdTime=2017-07-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=926910590ebd, moduleTitle=Lancet Haematol：MMR稳定慢性粒细胞白血病患者TKI降阶梯治疗是否可行？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=926910590ebd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384162, encodeId=8ce813841620b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, objectType=article, longId=101597, objectId=6d7510159e72, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d7510159e72, replyNumber=0, likeNumber=58, createdTime=2017-06-14, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d7510159e72, moduleTitle=合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d7510159e72)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384161, encodeId=07fc138416172, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=PLoS One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, objectType=article, longId=99620, objectId=b9739962011, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9739962011, replyNumber=0, likeNumber=37, createdTime=2017-05-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9739962011, moduleTitle=PLoS One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9739962011)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384160, encodeId=542c1384160f0, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Plos One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, objectType=article, longId=99253, objectId=4acb9925322, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4acb9925322, replyNumber=0, likeNumber=54, createdTime=2017-05-22, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4acb9925322, moduleTitle=Plos One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4acb9925322)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384159, encodeId=7d21138415988, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, objectType=article, longId=93392, objectId=9692933925e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9692933925e, replyNumber=0, likeNumber=59, createdTime=2017-03-27, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9692933925e, moduleTitle=[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9692933925e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384158, encodeId=dc4d1384158a1, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【专访张艰教授】EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应, objectType=article, longId=93043, objectId=34449304342, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34449304342, replyNumber=0, likeNumber=74, createdTime=2017-03-25, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34449304342, moduleTitle=【专访张艰教授】EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=34449304342)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384157, encodeId=d31e138415ee5, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=携带EGFR突变的非小细胞肺癌软脑膜转移（LM）更常见，且对TKI治疗反应好, objectType=article, longId=75467, objectId=9e90e54678c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e90e54678c, replyNumber=0, likeNumber=113, createdTime=2016-08-20, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e90e54678c, moduleTitle=携带EGFR突变的非小细胞肺癌软脑膜转移（LM）更常见，且对TKI治疗反应好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e90e54678c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384156, encodeId=f9df138415652, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, objectType=article, longId=74549, objectId=8dbde45490d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8dbde45490d, replyNumber=0, likeNumber=78, createdTime=2016-08-07, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8dbde45490d, moduleTitle=AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8dbde45490d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384155, encodeId=ba7913841557b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, objectType=article, longId=73238, objectId=b19de323897, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b19de323897, replyNumber=0, likeNumber=73, createdTime=2016-07-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b19de323897, moduleTitle=第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b19de323897)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384154, encodeId=20871384154de, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题, objectType=article, longId=69344, objectId=8fa26934452, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fa26934452, replyNumber=0, likeNumber=72, createdTime=2016-05-28, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fa26934452, moduleTitle=Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fa26934452)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384153, encodeId=4d8313841534f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）, objectType=article, longId=51535, objectId=af6f5153537, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af6f5153537, replyNumber=0, likeNumber=66, createdTime=2015-06-04, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af6f5153537, moduleTitle=ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af6f5153537)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384152, encodeId=114b1384152af, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2015 ：TKI抑制剂在肾癌辅助治疗中全线失败, objectType=article, longId=47647, objectId=c1634e647ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1634e647ff, replyNumber=0, likeNumber=62, createdTime=2015-03-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1634e647ff, moduleTitle=ASCO 2015 ：TKI抑制剂在肾癌辅助治疗中全线失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c1634e647ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384151, encodeId=041f138415196, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, objectType=article, longId=42035, objectId=067d42035e9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=067d42035e9, replyNumber=0, likeNumber=78, createdTime=2014-11-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=067d42035e9, moduleTitle=Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=067d42035e9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384150, encodeId=20b013841509d, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?, objectType=article, longId=40473, objectId=b6c5404e3cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6c5404e3cc, replyNumber=0, likeNumber=77, createdTime=2014-09-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6c5404e3cc, moduleTitle=CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6c5404e3cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384149, encodeId=f2b21384149e9, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, objectType=article, longId=37824, objectId=30183e824a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=30183e824a7, replyNumber=0, likeNumber=61, createdTime=2014-07-17, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=30183e824a7, moduleTitle=CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=30183e824a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384148, encodeId=bd3113841487b, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=三种第三代EGFR-TKI药物有望将来用于NSCLC, objectType=article, longId=36428, objectId=00fd3642874, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=00fd3642874, replyNumber=0, likeNumber=68, createdTime=2014-06-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=00fd3642874, moduleTitle=三种第三代EGFR-TKI药物有望将来用于NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=00fd3642874)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384147, encodeId=0d07138414e6f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, objectType=article, longId=35735, objectId=b22c35e35e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b22c35e35e3, replyNumber=0, likeNumber=53, createdTime=2014-06-03, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b22c35e35e3, moduleTitle=ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b22c35e35e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384143, encodeId=d391138414316, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2014：EGFR-TKI治疗后柔脑膜转移的NSCLC患者脑脊液EGFR突变阳性, objectType=article, longId=35671, objectId=7538356e136, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7538356e136, replyNumber=0, likeNumber=83, createdTime=2014-06-02, rootId=0, userName=zhouqu_8, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7538356e136, moduleTitle=ASCO 2014：EGFR-TKI治疗后柔脑膜转移的NSCLC患者脑脊液EGFR突变阳性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7538356e136)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384144, encodeId=79e0138414497, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果, objectType=article, longId=35691, objectId=a7ba35691f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7ba35691f6, replyNumber=0, likeNumber=97, createdTime=2014-06-02, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7ba35691f6, moduleTitle=ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a7ba35691f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384145, encodeId=08311384145a3, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析, objectType=article, longId=35696, objectId=1f4c3569670, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1f4c3569670, replyNumber=0, likeNumber=55, createdTime=2014-06-02, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1f4c3569670, moduleTitle=ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1f4c3569670)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Lancet Haematol：MMR稳定慢性粒细胞白血病患者TKI降阶梯治疗是否可行？

2017-07-20

lsj628 (审核中...)

前往app查看评论内容

#TKI#

合理选择EGFR-TKI，优化EGFR突变晚期NSCLC全程管理

2017-06-14

lsj628 (审核中...)

前往app查看评论内容

#TKI#

PLoS One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！

2017-05-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Plos One：非小细胞肺癌患者的EGFR突变比例与TKI治疗密切相关！

2017-05-22

lsj628 (审核中...)

前往app查看评论内容

#TKI#

[重磅]第三代TKI药物甲磺酸奥希替尼（AZD9291, Osimertinib）于中国快速获批

2017-03-27

lsj628 (审核中...)

前往app查看评论内容

#TKI#

【专访张艰教授】EGFR—TKI的优势促成EGFR突变的晚期非小细胞肺癌患者具有更好的疗效、更少的不良反应

2017-03-25

lsj628 (审核中...)

前往app查看评论内容

#TKI#

携带EGFR突变的非小细胞肺癌软脑膜转移（LM）更常见，且对TKI治疗反应好

2016-08-20

lsj628 (审核中...)

前往app查看评论内容

#TKI#

AIM：酪氨酸激酶抑制剂（TKIs）治疗CML会导致这些不良事件风险的增加

2016-08-07

lsj628 (审核中...)

前往app查看评论内容

#TKI#

第三代肺癌EGFR-TKI药物osimertinib 3期临床获得成功

2016-07-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Nature：肺癌第四代TKI有望问世，可以解决AZD9291耐药难题

2016-05-28

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2015：前瞻性TKI 直接比较的晚期肺鳞癌研究，阿法替尼总生存期更优（LUX-Lung 8）

2015-06-04

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2015 ：TKI抑制剂在肾癌辅助治疗中全线失败

2015-03-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Oncologist：阿法替尼治疗EGFR-TKIs获益的非小细胞肺癌患者进展后的经验分析

2014-11-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CSCO 2014：EGFR基因突变状态未知NSCLC治疗——TKIor化疗?

2014-09-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CSMO 2014 ：EGFR-TKI与NSCLC患者中枢神经系统转移

2014-07-17

lsj628 (审核中...)

前往app查看评论内容

#TKI#

三种第三代EGFR-TKI药物有望将来用于NSCLC

2014-06-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2014：c-met抑制剂INC280联合吉非替尼治疗EGFR-TKI耐药的NSCLC取得较好疗效

2014-06-03

zhouqu_8 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2014：EGFR-TKI治疗后柔脑膜转移的NSCLC患者脑脊液EGFR突变阳性

2014-06-02

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2014：T790M的异质性状态影响EGFR-TKI耐药NSCLC的化疗结果

2014-06-02

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO 2014：内分泌治疗/化疗+VEGFR-TKI治疗晚期乳腺癌的荟萃分析

2014-06-02

科室
- - 订阅+
  - 更多科室
工具
服务